Brief: Circio Enters Therapy Evaluation Agreement With Acuitas
15/04/2026 06:03
April 15 (Reuters) - Circio Holding ASA CRNA.OL: ENTERS IN VIVO CELL THERAPY EVALUATION AGREEMENT WITH ACUITAS THERAPEUTICS EVALUATION AGREEMENT FOR IN VIVO CAR-T CELL THERAPY CIRCVEC CIRCULAR RNA EXPRESSION TECHNOLOGY WILL BE TESTED TOGETHER WITH ACUITAS' PROPRIETARY T-CELL-TARGETED LIPID NANOPARTICLE Source text: ID:nObiK9JFva Further company coverage: CRNA.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Circio Holding ASA
See all newsBrief: Circio, Genassist Jointly Announce Gene Therapy Research Collaboration
Brief: Circio And Aavigen To Collaborate On In Heart Gene Therapy
Brief: Circio Commences Exercise Period For Warrants
Brief: Circio Holding Files New Circvec Patent Application
Brief: Circio, Traffikgene Enter Research Collaboration